Detection of circulating released platelets after renal transplantation.
In recipients of renal transplants, the biochemical defect(s) that underlies increased deposition of platelets in the graft and their shortened survival in the circulation are poorly understood. Forty-six recipients of kidney allografts, with and without rejection signs (13 acute rejections (ARs), 15 chronic rejections (CRs), and 18 functioning transplants (FTs), had lower platelet serotonin (5HT) and higher plasma beta-thromboglobulin than normal controls (NCs). These abnormalities were more pronounced in patients with ARs than with CRs but were also present in patients with FTs. All groups of transplant recipients showed an abnormal metabolism of platelet arachidonate, as expressed by low serum levels of thromboxane B2. In AR, plasma fibrinopeptide A (FPA) was significantly high whereas FPA levels were unchanged in CR and in FT. These findings suggest that in patients with renal transplants, the platelet release reaction has occurred in vivo, resulting in the secretion of granule-bound substances and the circulation of partially empty platelets. Vasoactive, mitogenic, and proaggregatory substances released from platelets might damage the graft and aggravate the rejection process.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000502:physiology*; D002470:Cell Survival; D002648:Child; D002908:Chronic Disease; D005260:Female; D005344:Fibrinopeptide A / Q000096:biosynthesis; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D012701:Serotonin / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood; D001620:beta-Thromboglobulin / Q000096:biosynthesis
D001620:beta-Thromboglobulin; D005344:Fibrinopeptide A; D012701:Serotonin; D013929:Thromboxane B2